Here it is folks enjoy!Pat Cox exerpt today.
NanoViricides Aces Another Animal Test
NanoViricides Inc. (OTCBB: NNVC) has just released data about tests of its anti-viral drug candidate, FluCide. NanoViricides, according to a company statement:
"reported dramatically improved anti-viral efficacy with its optimized FluCide drug candidates in its most recent animal studies. In the influenza mouse lethal infection model, animals treated with one of the optimized FluCide nanoviricide drug candidates survived beyond the stated full duration of study (21 days), and those treated with two additional drug candidates survived almost the full duration of the study. Animals in these three groups survived significantly longer (20.2-22.2 days) as compared to the animals treated with Oseltamivir (Tamiflu; only 8.3 days)."
There is simply no other flu treatment that comes close. For all practical purposes, influenza A is effectively over with the approval of this drug. This includes all the really scary flus we hear about, such as bird, swine and H1N1.
Remember, FluCide is not metabolized. It is polymer ligand bio/nanotech convergence. These nanoscale constructs work by mimicking human cells. The nanoviricides kill viruses wherever they encounter them. This can be in transgenic mice, petri dishes of human cells or test tubes of blood. It doesn't matter.
It hasn't been tested in humans yet, but only because they have to walk the FDA's straight and narrow. I haven't talked to any scientist working with this technology who has real fear that for some reason, it will not work when finally administered in humans. This is truly great news for humanity, the economy and owners of NanoViricides.
Obscured within the press release is more good news, by the way:
"Since then, the company says its FluCide program has progressed to process chemistry optimizations that were expected to provide additional benefits in terms of efficacy and safety improvements. The company now reports that these improvements have led to animal survival over the full defined 21-day duration of study for one drug candidate, with two additional drug candidates close behind the top candidate, at 20.2 and 20.4 days."
In other words, NanoViricides' brilliant chemical engineer Dr. Anil Diwan has learned a great deal about the technology of improving their drug candidates quickly. That's the "chemistry optimizations" referred to only casually. The statement goes on to quote the scientist chiefly responsible:
"'We believe that we may have more than quadrupled the efficacy of our FluCide candidates since the last study, based on the survival data,' said Anil R. Diwan, Ph.D., president, adding, 'We believe that current anti-influenza drugs would not match the efficacy levels achieved by our FluCide drug candidates, even at high dosages due to the former’s dose-limiting toxicities.'"
I'd also like to put the competition into perspective. There are universal vaccines on the way. In fact, I'm a total fan of our DNA vaccine company, Inovio Pharmaceuticals (AMEX: INO). I'm sure Dr. Joseph Kim will eventually have a vaccine for influenza, as well as various cancers, malaria and a range of serious diseases. However, we know how low vaccination rates will be. People don't like vaccines, and often for completely irrational reasons… but don't get me started.
Presented with a choice between a simple, cheap and effective cure for a disease OR a preventative vaccination, the majority will choose the cure. Once NanoViricides has a simple, inexpensive, needle-free cure for even the worst influenzas, I have to believe that NanoViricides will emerge a mega-biotech.
